A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures.

Trial Profile

A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Topiramate (Primary)
  • Indications Complex partial epilepsy; Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Acronyms PREVAIL
  • Sponsors Upsher-Smith
  • Most Recent Events

    • 28 Apr 2017 Results assessing efficacy and safety of USL255 and other second-generation antiepileptic drugs using patient data from PREVAIL, PREVAIL OLE and one more study (Guberman et al, 2002), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Results of pooled analysis from three phase I and two phase III studies assessing the differentiating features of Topiramate (extented release capsules and immediate release) presented at the 68th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Results from PREVAIL and PREVAIL OLE trials assessing adverse events presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top